Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment.

Thy, Sophia; Hommel, Alexandra; Meneceur, Sarah; Bartkowiak, Anna L; Schulz, Wolfgang A; Niegisch, Günter; Hoffmann, Michèle J

Thy, Sophia; Hommel, Alexandra; Meneceur, Sarah; Bartkowiak, Anna L; Schulz, Wolfgang A; Niegisch, Günter; Hoffmann, Michèle J.

Afiliação

Thy S; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Hommel A; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Meneceur S; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Bartkowiak AL; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Schulz WA; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Niegisch G; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Hoffmann MJ; Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.

Cancers (Basel) ; 13(6)2021 Mar 18.

Article em En | MEDLINE | ID: mdl-33803654

Palavras-chave

BRCAness; HR deficiency; PARP inhibitor; PLX51107; cisplatin resistance; epidrug; episensitization; romidepsin; talazoparib; urothelial carcinoma of the bladder

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article